Home > Publications database > Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia. > print

001     290602
005     20240918130108.0
024 7 _ |a 10.3324/haematol.2023.284346
|2 doi
024 7 _ |a pmid:38385304
|2 pmid
024 7 _ |a pmc:PMC11141665
|2 pmc
024 7 _ |a 0390-6078
|2 ISSN
024 7 _ |a 1592-8721
|2 ISSN
037 _ _ |a DKFZ-2024-01199
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Jaramillo, Sonia
|b 0
245 _ _ |a Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
260 _ _ |a Pavia
|c 2024
|b Ferrata Storti Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726657246_11602
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:W010#
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Gemtuzumab
|0 93NS566KF7
|2 NLM Chemicals
650 _ 7 |a Aminoglycosides
|2 NLM Chemicals
650 _ 7 |a glasdegib
|0 K673DMO5H9
|2 NLM Chemicals
650 _ 7 |a Benzimidazoles
|2 NLM Chemicals
650 _ 7 |a Phenylurea Compounds
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Gemtuzumab: therapeutic use
|2 MeSH
650 _ 2 |a Gemtuzumab: administration & dosage
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: drug therapy
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: diagnosis
|2 MeSH
650 _ 2 |a Antineoplastic Combined Chemotherapy Protocols: therapeutic use
|2 MeSH
650 _ 2 |a Antineoplastic Combined Chemotherapy Protocols: adverse effects
|2 MeSH
650 _ 2 |a Aminoglycosides: therapeutic use
|2 MeSH
650 _ 2 |a Aminoglycosides: administration & dosage
|2 MeSH
650 _ 2 |a Double-Blind Method
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Remission Induction
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Induction Chemotherapy
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Benzimidazoles
|2 MeSH
650 _ 2 |a Phenylurea Compounds
|2 MeSH
700 1 _ |a Krisam, Johannes
|b 1
700 1 _ |a Le Cornet, Lucian
|0 P:(DE-He78)a49833282b3e64d27fb1d08ceb6b2538
|b 2
|u dkfz
700 1 _ |a Kratzmann, Markus
|0 P:(DE-He78)ad1537a0b564af5f6cd80581a08a0788
|b 3
|u dkfz
700 1 _ |a Baumann, Lukas
|b 4
700 1 _ |a Eissymont, Olga
|b 5
700 1 _ |a Crysandt, Martina
|b 6
700 1 _ |a Görner, Martin
|b 7
700 1 _ |a Kayser, Sabine
|0 P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72
|b 8
|u dkfz
700 1 _ |a Krause, Stefan
|b 9
700 1 _ |a Schliemann, Christoph
|b 10
700 1 _ |a Gaska, Tobias
|b 11
700 1 _ |a Kaufmann, Martin
|b 12
700 1 _ |a Chemnitz, Jens
|b 13
700 1 _ |a Schaich, Markus
|b 14
700 1 _ |a Hoellein, Alexander
|b 15
700 1 _ |a Platzbecker, Uwe
|b 16
700 1 _ |a Kieser, Meinhard
|b 17
700 1 _ |a Müller-Tidow, Carsten
|b 18
700 1 _ |a Schlenk, Richard
|0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
|b 19
|e Last author
|u dkfz
773 _ _ |a 10.3324/haematol.2023.284346
|g Vol. 109, no. 6
|0 PERI:(DE-600)2805244-4
|n 6
|p 1973-1976
|t Haematologica
|v 109
|y 2024
|x 0390-6078
909 C O |p VDB
|o oai:inrepo02.dkfz.de:290602
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)a49833282b3e64d27fb1d08ceb6b2538
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)ad1537a0b564af5f6cd80581a08a0788
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-06-05T07:07:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-06-05T07:07:08Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2023-06-05T07:07:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-23
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-23
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-23
920 2 _ |0 I:(DE-He78)W010-20160331
|k W010
|l Klinische Studienzentrale
|x 0
920 1 _ |0 I:(DE-He78)W010-20160331
|k W010
|l Klinische Studienzentrale
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)W010-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21